Your browser doesn't support javascript.
loading
The Role of Mass Spectrometry in Hepatocellular Carcinoma Biomarker Discovery.
Shen, Eric Yi-Liang; U, Mei Ran Abellona; Cox, I Jane; Taylor-Robinson, Simon D.
Affiliation
  • Shen EY; Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan City 333, Taiwan.
  • U MRA; Clinical Metabolomics Core Laboratory, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan City 333, Taiwan.
  • Cox IJ; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W2 1NY, UK.
  • Taylor-Robinson SD; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W2 1NY, UK.
Metabolites ; 13(10)2023 Oct 08.
Article in En | MEDLINE | ID: mdl-37887384
ABSTRACT
Hepatocellular carcinoma (HCC) is the main liver malignancy and has a high mortality rate. The discovery of novel biomarkers for early diagnosis, prognosis, and stratification purposes has the potential to alleviate its disease burden. Mass spectrometry (MS) is one of the principal technologies used in metabolomics, with different experimental methods and machine types for different phases of the biomarker discovery process. Here, we review why MS applications are useful for liver cancer, explain the MS technique, and briefly summarise recent findings from metabolomic MS studies on HCC. We also discuss the current challenges and the direction for future research.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Metabolites Year: 2023 Document type: Article Affiliation country: Taiwan

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Metabolites Year: 2023 Document type: Article Affiliation country: Taiwan